SLN
Silence Therapeutics Plc - ADR

427
Mkt Cap
$238.06M
Volume
312,272.00
52W High
$7.78
52W Low
$1.97
PE Ratio
-3.01
SLN Fundamentals
Price
$5.04
Prev Close
$5.56
Open
$5.48
50D MA
$6.31
Beta
0.70
Avg. Volume
334,680.73
EPS (Annual)
-$0.9801
P/B
3.21
Rev/Employee
$373,070.71
Loading...
Loading...
News
all
press releases
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has earned a consensus recommendation of "Hold" from the six brokerages that are presently covering the stock, Marketbeat...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% - Should You Sell?
Silence Therapeutics (NASDAQ:SLN) Shares Down 0.7% - Should You Sell...
MarketBeat·5d ago
News Placeholder
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been given an average rating of "Hold" by the six research firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·27d ago
News Placeholder
Silence Therapeutics Announces Leadership Changes
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has...
Business Wire·1mo ago
News Placeholder
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat...
Business Wire·2mo ago
News Placeholder
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO...
Business Wire·3mo ago
News Placeholder
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Zacks·7mo ago
News Placeholder
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Zacks·8mo ago
News Placeholder
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Zacks·8mo ago
<
...
1
>

Latest SLN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.